Company News: Moderna (MRNA) Q1 revenues miss analysts’ expectations

Market news

6 May 2021

Company News: Moderna (MRNA) Q1 revenues miss analysts’ expectations

Moderna (MRNA) reported Q1 FY 2021 earnings of $2.84 per share (versus -$0.35 per share in Q1 FY 2020), beating analysts’ consensus estimate of $2.47 per share.

The company’s quarterly revenues amounted to $1.937 bln, missing analysts’ consensus estimate of $2.480 bln.

MRNA fell to $148.97 (-8.52%) in pre-market trading.

U.S.: Unit Labor Costs, q/q, Quarter I -0.3% (forecast -0.8%)

BoE's governor Bailey: 2021 GDP will recover strongly to pre-Covid levels

Market Focus

Material posted here is solely for information purposes and reliance on this may lead to losses. Past performances are not a reliable indicator of future results. Please read our full disclaimer

Open Demo Account & Personal Page

Personal area

support@teletradepartners.com

Risk Warning: Trading in the financial markets (including trading on margin) provides a wide range of opportunities and enables investors ready to take risks to make high profits, but it carries a potentially high level of risk of loss. Therefore, prior to trading you should take into careful consideration whether such operations are suitable for you in terms of your level of knowledge and financial situation.